Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lack Of Funding Stalls Major US FDA Cybersecurity Initiative

Executive Summary

A public-private partnership board long touted by top US FDA officials to help address cybersecurity threats has hit a funding wall. The agency received less than half of what it asked for in the FY 2019 budget for its digital efforts, including its cybersecurity strategy, leading it to make some tough choices.

You may also be interested in...

Head Of New Digital Health Center Looking For A Few Good FDA Staff

Bakul Patel, director of the US agency’s new Digital Health Center of Excellence, tells Medtech Insight he’s looking to hire staff that want to shape the digital health regulatory landscape.

Senate Wants To Keep FDA Device Center At Near-Current Levels In 2020 In 'Minibus' Funding Bill

The US Senate Appropriations Committee has drafted a “minibus” bill covering funding in fiscal year 2020 for five agencies – including the FDA – that would give the agency's device center only $387m. That would keep the center’s spending level approximately the same as it was in FY 2019. The Senate’s proposed spending level is in sharp contrast to what the US House wants for the device center, which is $420m.

Continuing Resolution Passage Means FDA Funds Stuck At 2019 Levels Through November

The US Senate and House have both approved continuing resolution bills that President Trump is expected to sign shortly to keep the federal government running through 21 November – but that means that the FDA will be stuck at its 2019 funding level until then.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts